National and subnational plans for primary prevention and early detection of oral and oropharyngeal cancer: a scoping review
Abstract
This scoping review maps primary prevention and early detection strategies for oral and oropharyngeal cancer across national cancer plans and noncommunicable disease plans from all World Health Organization Member States. Following PRISMA-ScR guidelines, bibliographic search was performed on key organization websites until March 2023. Of the 194 countries assessed three had subnational plans, resulting in 264 self-governing political entities and similar with revised plans. Among these, 124 (47%) addressed oral and oropharyngeal cancer risk factors and preventive strategies, including 73 national and 51 subnational plans (one from Australia, two from the United Kingdom and 48 from the United States) across 76 (39.2%) countries. Southeast Asia led with 81.8% self-governing political entities mentioning oral and oropharyngeal cancer risk factors and preventive strategies, followed by the Americas (63.5%). Western Pacific and Eastern Mediterranean regions had the lowest coverage with 24.2% and 23.8%, respectively. Tobacco use was the most discussed oral and oropharyngeal cancer risk factor in primary prevention plans (63.7%), followed by HPV infection (54%) and alcohol consumption (35.5%). Opportunistic examination was the most common strategy for early detection, recommended by 29% of self-governing political entities, followed by screening in high-risk individuals (14.5%), self-examination (5.6%), and population-based screening (2.4%). Despite the high oral and oropharyngeal…
Read the paper
Related studies
- Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
- Comparative effects of e-cigarette smoking on periodontal status, salivary pH, and cotinine levels
- Association between exposure to environmental pollutants and increased oral health risks, a comprehensive review
- Influence of gestational window on offspring vascular health in rodents with in utero exposure to electronic cigarettes
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials
- Nicotine in electronic cigarettes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.